Garcia, Jessica
Gauthier, Arnaud
Lescuyer, Gaëlle
Barthelemy, David
Geiguer, Florence
Balandier, Julie
Edelstein, Daniel L.
Jones, Frederick S.
Holtrup, Frank
Duruisseau, Mickael
Grolleau, Emmanuel
Rodriguez-Lafrasse, Claire
Merle, Patrick
Couraud, Sébastien
Payen, Léa http://orcid.org/0000-0002-1599-5886
Article History
Accepted: 3 February 2021
First Online: 3 March 2021
Declarations
:
: This work was supported by research grants from Astra-Zeneca (London, UK).
: Frank Holtrup, Frederick S. Jones, and Daniel L. Edelstein are employees of Symex Inostics. Sébastien Couraud has no potential conflict of interest with Astra Zeneca, Sysmex Inostics, Roche, and Boehringer Ingelheim that is directly relevant to the content of this article. Jessica Garcia, Arnaud Gauthier, Gaëlle Lescuyer, David Barthelemy, Florence Geiguer, Julie Balandier, Mickael Duruisseau, Emmanuel Grolleau, Claire Rodriguez-Lafrasse, Patrick Merle, Sébastien Couraud, and Léa Payen have no conflicts of interest that are directly relevant to the content of this article.
: All samples sent to the laboratory for EGFR routine screening within cfDNA between September 2018 and February 2020 were included in this retrospective cohort study. For each sample, medical data were collected through mandatory prescription sheet attached to each sample and edited by the prescribing physician.
: All participants consented to participate in the study.
: Not applicable.
: Not applicable.
: The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.